SARS vaccines: where are we?
- 1 July 2009
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 8 (7) , 887-898
- https://doi.org/10.1586/erv.09.43
Abstract
In this review, the current state of vaccine development against human severe acute respiratory syndrome (SARS) coronavirus, focusing on recently published data is assessed. We discuss which strategies have been assessed immunologically and which have been evaluated in SARS coronavirus challenge models. We discuss inactivated vaccines, virally and bacterially vectored vaccines, recombinant protein and DNA vaccines, as well as the use of attenuated vaccines. Data regarding the correlates of protection, animal models and the available evidence regarding potential vaccine enhancement of SARS disease are discussed. While there is much evidence that various vaccine strategies against SARS are safe and immunogenic, vaccinated animals still display significant disease upon challenge. Current data suggest that intranasal vaccination may be crucial and that new or combination strategies may be required for good protective efficacy against SARS in humans.Keywords
This publication has 144 references indexed in Scilit:
- Pathogenicity of severe acute respiratory coronavirus deletion mutants in hACE-2 transgenic miceVirology, 2008
- Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoVVaccine, 2007
- Persistent memory CD4+ and CD8+ T-cell responses in recovered severe acute respiratory syndrome (SARS) patients to SARS coronavirus M antigenJournal of General Virology, 2007
- Type IVB Pilus Operon Promoter Controlling Expression of the Severe Acute Respiratory Syndrome-Associated Coronavirus Nucleocapsid Gene in Salmonella enterica Serovar Typhi Elicits Full Immune Response by Intranasal VaccinationClinical and Vaccine Immunology, 2007
- Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogensProceedings of the National Academy of Sciences, 2007
- Animal models and vaccines for SARS-CoV infectionVirus Research, 2007
- Vaccines to prevent severe acute respiratory syndrome coronavirus-induced diseaseVirus Research, 2007
- Severe acute respiratory syndrome coronavirus nsp1 protein suppresses host gene expression by promoting host mRNA degradationProceedings of the National Academy of Sciences, 2006
- An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirusNature Medicine, 2004
- A DNA vaccine induces SARS coronavirus neutralization and protective immunity in miceNature, 2004